



10-16-BB Attorney Docket No. 037003-0275463
Client Ref. No. 1992-30-0029CP2 1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Anderson, et al.

Serial No: 08/921,060

Filed: August 29, 1997

Title: EX VIVO TREATMENT OF
ALLOGENIC AND XENOGENIC
DONOR T CELLS CONTAINING
COMPOSITIONS (BONE
MARROW) USING GP39
ANTAGONISTS AND USE
THEREOF

RECEIVED
OCT 14 2003
TECH CENTER 1600/2900

) Examiner: Schwadron, R.

) Art Unit: 1644

) Certificate of Mailing Under §1.10

) I, Patricia Munoz, hereby certify that this paper
) or fee is being deposited with the United States
) Postal Service as Express Mail Post Office to
) Addressee service, Express Mailing Label No.
) EL 989 437 735 US, under 37 C.F.R. § 1.10 on
) the date indicated below and is addressed to the
) Commissioner for Patents, P.O. Box 1450,
) Alexandria, VA 22313-1450 on this date.

) Date: Oct 14, 2003

) By: Patricia Munoz

SUPPLEMENTAL

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants request that the information on the attached Form PTO-1449 be considered by the Office during the pendency of the above-entitled application, pursuant to 37 C.F.R. 1.97. In accordance with 37 C.F.R. 1.97(h), the filing of the Supplemental Information Disclosure Statement shall not constitute an admission that any information cited therein is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b). In the interest of full and complete disclosure to the Office, some or all of the art cited herein may not be considered by Applicant(s) or the Undersigned to be material under the standards of materiality defined in

C.F.R. 1.56(b), enacted March 16, 1992, as amended September 8, 2000, and may merely be technical background which may be of interest to the Examiner.

In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

Since an Office Action on the merits has issued for this application, Applicants believe that a fee is due. Please charge any fees that may be necessary to Deposit Account No. 03-3975, Order No. 037003-0275463. A duplicate copy of this transmittal is enclosed for accounting purposes.

Respectfully submitted,

Date: October 14, 2003



Suzanne L. Biggs
Registration No. 30,158 for

Thomas A. Cawley, Jr.
Registration No. 40,944
PILLSBURY WINTHROP LLP
1600 Tysons Boulevard
McLean, VA 22102
Telephone: (703) 905-2000
Fax Line: (703) 905-2500
Direct Line: (858) 509-4095

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office



Atty. Dkt. No.	M#	Client Ref.
	037003-0275463	1992-30-0029CP2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Anderson, et al.
Appln. No.: 08/921,060
Filing Date: August 29, 1997
Examiner: Schwadron, R. Group Art Unit: 1644

Date: October 14 2003

Page 1 of 2

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR	5,648,267	07/1997	Reff		320.1	
BR						

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
CR 0 125 023 A1	11/1984	EP	Cabilly, et al.		
DR 0 125 023 B1	11/1984	EP	Cabilly, et al.		
ER 0 125 023 B2	03/2002	EP	Cabilly, et al.		
FR 0 173 494 A2	03/1986	EP	Morrison, et al.		
GR WO 88/04936	07/1988	WO	Robinson, et al.		
HR					

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Adams, R.A. et al., Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, SB-2, <i>Can Res</i> 28:1121-1125 (1968).			
Adams, Richard, Formal Discussion: The role of transplantation in the experimental investigation of human leukemia and lymphoma, <i>Can. Res.</i> 27:2479-2482 (1967).			
Appelbaum, F.R., Radiolabeled Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma. <i>Hem. Onc. Clinics of N.A.</i> 5(5):1013-1025 (1991).			
Armitage, J.O. et al., Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP), <i>Cancer</i> 50:1695 (1982).			
Boulianne, G.L. et al., Production of functional chimaeric mouse/human antibody, <i>Nature</i> 312:643 (December 1984).			
Brunner, K.T. et al., Quantitative assay of the lytic action of immune lymphoid cells on ⁵¹ Cr-labeled allogeneic target cells <i>in vitro</i> ; inhibition by isoantibody and drugs, <i>Immunology</i> 14:181-189 (1968).			
Chomczynski, P. et al., Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, <i>Anal. Biochem.</i> 162:156-159 (1987).			
Eary, J.F. et al, Imaging and Treatment of B-Cell Lymphoma, <i>J. Nuc. Med.</i> 31/8:1257-1268 (1990).			
Einfeld, D.A. et al., Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains, <i>EMBO</i> 7:711 (1988)			
Goldenberg, D.M. et al., Targeting, dosimetry and radioimmunotherapy of B-Cell lymphomas with iodine-131-labeled LL2 monoclonal antibody, <i>J. Clin. Onc.</i> 9/4:548-564 (1991).			
Kaminski, M.G. et al., "Radioimmunotherapy of B-cell lymphoma with [¹³¹ I] anti-B1 (anti-CD20) antibody, <i>NEJM</i> 329/7 (1993).			

		Liu, A.Y. <i>et al.</i> , Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity. <i>J. Immun.</i> 139/10:3521-3526 (1987).				
		Marx, Antibodies made to order, <i>Science</i> 229 455 (August 1985).				
		Morrison, S.L. <i>et al.</i> , Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains, <i>PNAS</i> 81:6851-6854 (November 1984).				
		Morrison, Transfectomas provide novel chimeric antibodies, <i>Science</i> 229:1202-1207 (September 1985).				
		Munro, Uses of chimaeric antibodies, <i>Nature</i> 312:597 (December 1984).				
		Neuberger, M.S. <i>et al.</i> , A hapten-specific chimaeric IgE antibody with human physiological effector function, <i>Nature</i> 314:268 (March 1985).				
		Press <i>et al.</i> , Monoclonal antibody 1F5 (Anti-CD20) serotherapy of human B cell lymphomas, <i>Blood</i> 69(2):584-591 (1987)				
		Press, O.W. <i>et al.</i> , "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support." <i>New England Journal of Medicine</i> 329/17: 1219-12223 (1993).				
		Press, O.W. <i>et al.</i> , "Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody, <i>J. Clin. Onc.</i> 7/8:1027-1038 (1989)				
		Robinson, R.D. <i>et al.</i> , "Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities," <i>Hum. Antibod. Hybridomas</i> 2:84-93 (1991).				
		Sahagan <i>et al.</i> , A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen, <i>J. Immunol.</i> 137:1066-1074 (1986).				
		Scharff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, <i>Harvey Lectures</i> 69:125-143 (1974).				
		Shulman, M. <i>et al.</i> , A better cell line for making hybridomas secreting specific antibodies, <i>Nature</i> 276:269 (1978).				
		Srivastava, S.C., <i>et al.</i> , Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies, <i>Nucl. Med. Bio.</i> 18(6): 589-603 (1991).				
		Sun, L.K. <i>et al.</i> , Chimeric antibodies with 17-1A-derived variable and human constant regions, <i>Hybridoma</i> 5/1:517 (1986).				
		Tan <i>et al.</i> , A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells, <i>J. Immunol.</i> 135:8564 (November 1985).				
		Urlaub, G. <i>et al.</i> , Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions." <i>Som. Cell & Mol. Gen.</i> 12/6:555-566 (1986).				
		Valentine, M.A. <i>et al.</i> , Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, <i>J. Biol. Chem.</i> 264(19):11282-11287 (1989).				

Examiner	Date Considered:
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>	